TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03302689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Solution
Description: TAP-block with Levobupivacaine 0,3% - 25 ml from each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Solution
Description: TAP-block with Ropivacaine 0,3% - 25 ml from each side
Study: NCT02590276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: characterization
Study: NCT03612128

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
Study: NCT01056653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dose
Description: Two intevention home visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Four intervention home visits

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Comparison Group
Description: One home visit, information only
Study: NCT02753868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Description: Participants will receive a standard hemodialysis treatment during the study period
Study: NCT02142335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
Study: NCT02753868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Description: Participants will receive a standard hemodialysis treatment during the study period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Description: Participants will receive a standard hemodialysis treatment during the study period
Study: NCT00299104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folate
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Intravenous repeating dose
Study: NCT02671760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: 3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
Study: NCT00299104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Intravenous repeating dose
Study: NCT01645735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone plus vancomycin
Description: Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
Study: NCT03593122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WO2085 Moisturising Cream
Description: Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
Study: NCT03770208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: Lidocaine
Description: IV Lidocaine bolus plus infusion. Weight based.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Standard Care + Placebo
Description: Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
Study: NCT02088099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex clinical intervention
Description: The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
Study: NCT00299104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT02088099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
Study: NCT00299104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT01891396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid and TH (Cingal®)
Description: Injection into knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid (Monovisc®)
Description: Injection into knee

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline placebo packaged to look identical to comparator syringes. Injection into knee.
Study: NCT01995526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Study: NCT01229046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticarcillin-clavulanic acid
Description: 5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
Study: NCT02058004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Description: Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
Study: NCT01304615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decrease Energy Density of the Diet
Description: Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease Energy Density of the Diet
Description: Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increase Steps per Day
Description: Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
Study: NCT03375775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
Description: According to standardized clinical protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No immunotherapy, symptomatic treatment
Description: These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
Study: NCT01304615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Steps per Day
Description: Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of Self-made Meals
Description: Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
Study: NCT03925103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D VATS lobectomy
Description: pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D VATS lobectomy
Description: pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
Study: NCT02220192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal LEEP
Description: Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
Study: NCT04512820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUCLEAR tissue removal system
Description: evacuation of POC using the TRUCLEAR tissue removal system
Study: NCT01496053

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AndoSan
Description: AndoSan 30 ml x 2 for 21 days
Study: NCT02671760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: 2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01496053

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sugar Extract
Description: Sham comparator
Study: NCT03586024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: dose of pembrolizumab will be 200 mg IV every 3 weeks
Study: NCT03616600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-O-Correct Lens
Description: Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
Study: NCT03274947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar TMS
Description: Cerebellar transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar TMS
Description: Cerebellar transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar TMS
Description: Cerebellar transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar TMS
Description: Sham cerebellar transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar TMS
Description: Sham cerebellar transcranial magnetic stimulation
Study: NCT02485509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500/Placebo
Description: VM-1500 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500/Placebo
Description: VM-1500 or Placebo
Study: NCT04146233

Intervention type: OTHER
Group type: OTHER
Intervention: Point of care gastric ultrasound
Description: Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).

Intervention type: OTHER
Group type: OTHER
Intervention: Point of care gastric ultrasound
Description: Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
Study: NCT01651039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
Study: NCT05351840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloV
Description: Treatment A, Tablet, Oral, QD for 7 Days
Study: NCT01651039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
Study: NCT02453178

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
Study: NCT01847274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Niraparib
Description: Niraparib vs placebo 2:1 ratio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05351840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Treatment B, Tablet, Oral, QD for 10 Days
Study: NCT03375892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free breathing during radiation
Description: The patient will be instructed to breathe freely.
Study: NCT00830934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individual care
Description: The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group care
Description: The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
Study: NCT05771350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online hemodiafiltration
Description: 20 patients on regular hemodialysis received online hemodiafiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high flux hemodialysis
Description: 20 patients on regular hemodialysis received high flux hemodialysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low flux hemodialysis
Description: 20 patients on regular hemodialysis received low flux hemodialysis
Study: NCT02641912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biotene mouthwash
Description: During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Mineral Water
Description: During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use.
Study: NCT01651312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled YM178
Description: oral solution (1.85 MBq)
Study: NCT03722316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Nature Video
Description: An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Nature Video
Description: An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Video
Description: This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral Video
Description: This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.
Study: NCT04244058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine + L-DOPA
Description: Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMDA blocker
Description: NMDA blocker
Study: NCT04452318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933 + REGN10987
Description: Subcutaneous (SC) or Intramuscular (IM) injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC or IM injections
Study: NCT01665768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
Study: NCT03459157

Intervention type: DRUG
Group type: OTHER
Intervention: HIV prevention package including PrEP
Description: All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Study: NCT04358289

Intervention type: OTHER
Group type: OTHER
Intervention: Community education
Description: Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels

Intervention type: OTHER
Group type: OTHER
Intervention: Community education
Description: Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
Study: NCT02769819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible fiberscope
Description: * Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation.
Study: NCT02387242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose of rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose of rifampicin
Study: NCT05351840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloVA
Description: Treatment C, Tablet, Oral, QD for 7 Days
Study: NCT03306472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 40 MG
Description: Progesterone Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160 MG
Description: Progesterone Agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Aromatase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase Inhibitor
Study: NCT01329341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service Dogs
Description: Service dogs will be trained to help Veterans with PTSD